** Shares of Nuvectis Pharma NVCT.O down 22% to $22.25 before the bell after $100 mln follow-on offering priced

** NVCT late Mon sold 5 mln shares at $20, a 30% discount to their record-high close of $28.53

** Cantor Fitzgerald sole bookrunner

** Fort Lee, New Jersey-based NVCT, which has 26.5 mln shares outstanding, intends to use net offering proceeds to advance programs of NXP100, NXP200, and NXP900 or any future product candidate, among other purposes

** On Jun 22, NVCT said it secured licensing deal with China's Haisco 002653.SZ for experimental drugs NXP100 and NXP200, targeting complement-mediated diseases and cancer to broaden its pipeline

** NVCT shares have nearly tripled this month through Mon

** All 5 analysts rate the shares "buy" and their median PT is $30, per LSEG data